Trial · NCT00174915
Results by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 50
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL). | Febuxostat 80 mg QD | 48 | Percentage of subjects | ||
| Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL). | Febuxostat 120 mg QD | 65 | Percentage of subjects | ||
| Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL). | Febuxostat 240 mg QD | 69 | Percentage of subjects | ||
| Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL). | Allopurinol QD | 22 | Percentage of subjects | ||
| Percentage of Subjects Whose Last Three Serum Urate Levels Are <6.0 Milligram Per Deciliter (mg/dL). | Placebo QD | 0 | Percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28 | Febuxostat 80 mg QD | 76 | Percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28 | Febuxostat 120 mg QD | 87 | Percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28 | Febuxostat 240 mg QD | 94 | Percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28 | Allopurinol QD | 41 | Percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Week 28 | Placebo QD | 1 | Percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit | Febuxostat 80 mg QD | 72 | Percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit | Febuxostat 120 mg QD | 79 | Percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit | Febuxostat 240 mg QD | 92 | Percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit | Allopurinol QD | 39 | Percentage of subjects | ||
| Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Final Visit | Placebo QD | 1 | Percentage of subjects | ||
| Percent Change From Baseline in Serum Urate Levels at Week 28. | Febuxostat 80 mg QD | -47.6 | Standard Deviation 15.86 | Percent change | |
| Percent Change From Baseline in Serum Urate Levels at Week 28. | Febuxostat 120 mg QD | -54.9 | Standard Deviation 14.97 | Percent change | |
| Percent Change From Baseline in Serum Urate Levels at Week 28. | Febuxostat 240 mg QD | -67.8 | Standard Deviation 18.18 | Percent change | |
| Percent Change From Baseline in Serum Urate Levels at Week 28. | Allopurinol QD | -34.4 | Standard Deviation 14.21 | Percent change | |
| Percent Change From Baseline in Serum Urate Levels at Week 28. | Placebo QD | -3.6 | Standard Deviation 13.85 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00174915/results